Background
==========

The different contractile and metabolic functions of individual skeletal muscles in the body are caused by a different muscle fiber distribution. Two major types of muscle fibers, which differ in their myosin heavy-chain (MHC) isoforms and their enzymatic capacity \[[@B1]\], can be distinguished. Type I fibers are mitochondria-rich, have a high oxidative capacity utilizing mostly oxidative phosphorylation \[[@B2],[@B3]\], and are myoglobin-rich with red appearance. Type II fibers (subdivided in IIa, IIb and IId/x) have a lower oxidative capacity due to fewer mitochondria content than type I muscle fibers and thus depend on glycolytic metabolism to generate ATP.

Interestingly, muscle fiber distribution is altered by genetic and/or high fat diet-induced obesity due to induction of fiber transition from type I to type II thereby leading to a change of the muscle's metabolic phenotype \[[@B4]-[@B7]\]. The resulting reduced type I fiber content is associated with mitochondrial dysfunction characterized by an impaired mitochondrial oxidative enzyme capacity of skeletal muscle \[[@B8]\]. Noteworthy, genetic and/or high fat diet-induced obesity and diabetes cause an impairment of carnitine status \[[@B9]-[@B11]\], whereas normalization of carnitine status due to carnitine supplementation reverses mitochondrial dysfunction under these conditions \[[@B4],[@B9],[@B10],[@B12],[@B13]\]. At large, these findings indicate that carnitine supplementation through normalizing carnitine status is able to prevent type I to type II fiber transition and thereby the metabolic shift from oxidative to glycolytic of skeletal muscle under unloading conditions or metabolic stress.

Obesity- and diabetes-induced type I to type II fiber transition and decreases of oxidative capacity of skeletal muscle has been explained by down-regulation of peroxisome proliferator-activated receptor γ, coactivator-1α (PGC-1α) and peroxisome proliferator-activated receptor δ (PPARδ) \[[@B4],[@B9],[@B14]\]. Both, PGC-1α and PPARδ are critical regulators of genes involved in type II to type I fiber transition, mitochondrial biogenesis, cellular and mitochondrial fatty acid uptake, β-oxidation, carnitine uptake, tricarboxylic acid cycle, respiratory chain, and angiogenesis \[[@B15]-[@B20]\]. Due to these functions PPARδ and PGC-1α are typically higher expressed in oxidative type I muscle fibers than in glycolytic type II muscle fibers \[[@B15],[@B21]\]. Interestingly, carnitine supplementation was reported to increase expression of PGC-1α and PPARδ in rodent models of unloading \[[@B4]\], and genetic and diet-induced obesity and diabetes \[[@B10]\]. Based on these observations we hypothesized that carnitine supplementation through inducing PGC-1α and PPARδ in skeletal muscle counteracts obesity and/or diabetes-induced muscle fiber transition from type I to type II and restores the muscle fiber distribution and the muscle oxidative metabolic phenotype observed during non-obese and non-diabetic states. As a model object we used obese Zucker rats, an established genetic model of obesity, insulin resistance, and metabolic syndrome, which were fed either a carnitine supplemented or a control diet with a low native carnitine concentration for 4 wk. Lean Zucker rats served as healthy non-obese and non-diabetic controls.

Methods
=======

Animals and housing
-------------------

24 male obese (fa/fa) Zucker rats (Crl:ZUC-*Lepr*^*fa*^; Charles River, France) were randomly divided in two groups of 12 rats each. They had an initial body weight of 357 ± 4 (mean ± SEM) g and aged 8--10 weeks. In addition, 12 male heterozygous lean (fa/+) Zucker rats were used for the lean control group. They were also 8--10 weeks old and had an initial body weight of 271 ± 3 (mean ± SEM) g. The rats were kept in Macrolon cages in a controlled environment with a 12-h light--dark cycle. All experimental procedures followed established guidelines for the care and handling of laboratory animals and were approved by the local Animal Care and Use Committee.

Diets and feeding
-----------------

The rats received two different semi-purified diets which were composed according to the recommendations of the American Institute of Nutrition (AIN)-93G \[[@B22]\]. The first diet, which contained no carnitine supplement and had a very low carnitine concentration of below \< 5 mg carnitine/kg diet, was given to the lean control and the obese control group. The second diet containing 3 g carnitine/kg diet was given to the obese carnitine group. Both diets contained (g/kg diet): corn starch, 530; casein, 200; saccharose, 100; soybean oil, 70; cellulose, 50; minerals, 30; vitamins, 20. Carnitine was added to the obese carnitine diet at the expense of corn starch. The diets were prepared by mixing the dry components and subsequent pelleting using a standard pelleting device (Kahl Laborpressanlage Typ 14--175; Reinbek, Germany). Feed and water was available *ad libitum* and feed intake was recorded every week during the 28 days of the experiment.

Sample collection
-----------------

The rats of all groups were decapitated under CO~2~ anesthesia. Blood samples were taken into EDTA polyethylene tubes (Sarstedt, Nürnbrecht, Germany) and plasma was collected by centrifugation (1,100 × g; 10 min, 4°C). *M. rectus femoris* was excised, immediately snap-frozen with liquid nitrogen and stored at −80°C pending analysis.

Muscle fiber typing
-------------------

For muscle fiber typing serial cross-sections of 30 μm thickness from *M. rectus femoris* were prepared using a cryostat microtome at −25°C and muscle fibers were identified by their different inactivation of myofibrillar actomyosin ATPase during acid preincubation, using a modified method according to Hämäläinen and Pette \[[@B23]\], as recently described \[[@B24]\].

Determination of plasma lipids
------------------------------

The concentration of triglycerides in plasma was determined using enzymatic reagent kits (refs. 157609990314 and 113009990314) \[[@B25]\]. Concentration of non-esterified fatty acids (NEFA) in plasma was measured using the NEFA kit from Wako Chemicals (ref. RD291001200R).

Determination of carnitine levels in plasma and muscle
------------------------------------------------------

Tandem mass spectrometry was used for determining the concentrations of free carnitine and acetyl carnitine in plasma and muscle. Total carnitine was calculated as the sum of free carnitine and acetyl-carnitine. Deuterated carnitine-d3 (Cambridge Isotype Laboratories, Andover, MA, USA) was used as internal standard, according the method of Hirche et al. \[[@B26]\].

RNA isolation and qPCR analysis
-------------------------------

Total RNA was isolated from 20 mg skeletal muscle tissue using Trizol™ reagent (Invitrogen, Karlsruhe, Germany) according to the manufacturer's protocol. Isolated RNA was stored at −80°C. RNA concentration and purity were estimated from the optical density at 260 and 280 nm (Infinite 200 M micro plate reader, Tecan, Männedorf, Switzerland). The integrity of the RNA was also verified by 1% agarose gel electrophoresis, which showed intact bands corresponding to the 18S and 28S ribosomal RNA subunits. cDNA synthesis and qPCR analysis were performed as described recently in detail \[[@B27]\]. Features of gene-specific primer pairs are listed in Table [1](#T1){ref-type="table"}. Calculation of gene expression data and normalization by GeNorm normalization factor were carried out as described recently \[[@B27]\]. In this study the three most stable out of six tested potential reference genes were CANX, TOP1 and YWHAZ in *M. rectus femoris* (Table [2](#T2){ref-type="table"}). Means and SEM were calculated from normalized expression data for samples of the same treatment group. The mean of the control obese group was set to 1 and means and SEM of the other treatment groups were scaled proportionally. Data on qPCR performance for each gene measured in skeletal muscle are shown in Table [1](#T1){ref-type="table"}.

###### 

Characteristics of primers used for qPCR

  **Gene symbol**          **Primer sequence (forward, reverse; from 5′ to 3′)**   **NCBI GeneBank**    **Product size (bp)**   **Slope**   **R**^**2\#**^   **Efficiency\***
  ------------------------ ------------------------------------------------------- ------------------- ----------------------- ----------- ---------------- ------------------
  ACADL                    AAGGATTTATTAAGGGCAAGAAGC                                NM_012819                   380 bp             −3.88         0.998              1.81
  GGAAGCGGAGGCGGAGTC                                                                                                                                        
  ACADM                    CAAGAGAGCCTGGGAACTTG                                    NM_016986                   154 bp             −3.38         0.999              1.98
  CCCCAAAGAATTTGCTTCAA                                                                                                                                      
  ATP5B                    GCACCGTCAGAACTATTGCT                                    NM_134364                   203 bp             −3.59         0.999              1.90
  GAATTCAGGAGCCTCAGCAT                                                                                                                                      
  CANX                     CCAGATGCAGATCTGAAGAC                                    NM_172008                   175 bp             −2.75         0.999              2.31
  CTGGGTCCTCAATTTCACGT                                                                                                                                      
  CD36                     TCGTATGGTGTGCTGGACAT                                    NM_031561                   358 bp             −3.28         0.996              2.02
  GGCCCAGGAGCTTTATTTTC                                                                                                                                      
  CPT1B                    GCAAACTGGACCGAGAAGAG                                    NM_013200                   180 bp             −3.32         0.988              2.00
  CCTTGAAGAAGCGACCTTTG                                                                                                                                      
  FABP3                    ACCATCCACTGCCGTCTTAC                                    NM_013177                   310 bp             −3.20         0.957              2.05
  CCCCGATGCGTAGGTATTCT                                                                                                                                      
  HK2                      GATGGAATCGAGAAGGCCTA,                                   NM_012735                   220 bp             −3.63         1.000              1.89
  GTTTCTTGTAGACGGAGCCA                                                                                                                                      
  LPL                      GAGATTTCTCTGTATGGCACA                                   NM_012598                   276 bp             −3.34         0.992              1.99
  CTGCAGATGAGAAACTTTCTC                                                                                                                                     
  MDH1                     CAGACAAAGAAGAGGTTGCC,                                   NM_033235                   206 bp             −3.40         0.994              1.97
  CGTCAGGCAGTTTGTATTGG                                                                                                                                      
  MYH1                     GCAGACTCTCCCACTGGGCTG                                   NM_001135158                 83 bp             −3.16         0.953              2.07
  GAGCAGCCTCCCCGAAAACGG                                                                                                                                     
  MYH2                     GCTGATCGAAATGCTGCTGA                                    NM_001135157                124 bp             −3.38         0.990              1.98
  GTCAATAGCACTATCCGTGG                                                                                                                                      
  MYH4                     CCAGTCCATCCTGATTACTG                                    NM_019325                    74 bp             −3.48         0.988              1.94
  CAAAGTACTGGATGACACGC                                                                                                                                      
  MYH7                     ATTGCCGAGTCCCAGGTCAACA                                  NM_017240                   127 bp             −3.24         0.944              2.03
  GCTCCAGGTCTCAGGGCTTCAC                                                                                                                                    
  PFKM                     TCCTGGTTGGCTCAATCGAC                                    NM_031715                   297 bp             −3.75         0.998              1.85
  TGTTGAGACGAGAACCACGG                                                                                                                                      
  PKM                      ACCTGGGCATTGAGATTCCG                                    NM_053297                   314 bp             −3.69         0.997              1.87
  TCGCGCAAGCTCTTCAAACA                                                                                                                                      
  PPARD                    GCAGAGCTATGACCAGGCCTGCA                                 NM_013141                   151 bp             −3.29         0.990              2.01
  GTGCTCTGGTCCCCCGTTGA                                                                                                                                      
  PPARGC1A                 CTCTTTGCCCAGATCTTCCT                                    NM_031347                   145 bp             −3.93         0.999              1.80
  ATGTTCGCGGGCTCATTGTT                                                                                                                                      
  PPARGC1B                 CATATAAGCCCATGGAGGAG                                    NM_176075                   476 bp             −3.25         0.978              2.03
  CAGCCCAAAGTGCTTTGTGA                                                                                                                                      
  RPL13                    CTTAAATTGGCCACGCAGCT                                    XR_086310                   198 bp             −3.48         0.998              1.94
  CTTCTCAACGTCTTGCTCTG                                                                                                                                      
  SDHA                     TGGACCTTGTCGTCTTTGG                                     NM_130428                    88 bp             −3.90         0.997              1.80
  TTTGCCTTAATCGGAGGAAC                                                                                                                                      
  SLC2A4                   GAGTTATGTGTCCATCGTGG                                    NM_012751                   187 bp             −2.59         0.953              2.40
  CGCAACATACTGGAAACCCA                                                                                                                                      
  SLC22A5                  GAACTCACGAGCCTCGCACGC                                   NM_019269                   117 bp             −3.75         0.997              1.85
  TCGTCGTAGTCCCGCATGCC                                                                                                                                      
  SLC25A20                 AGCCCACCTGTTATCCACTG                                    NM_053965                   178 bp             −3.32         0.988              2.00
  TGTGCAAAAAGAGCCTTCCT                                                                                                                                      
  SLC27A1                  GTATCTGCTGGACCTTCGC                                     NM_053580                   243 bp             −3.48         0.990              1.94
  CATAAATGAGGGCCTTGGCA                                                                                                                                      
  TOP1                     GAAGAACGCTATCCAGAAGG                                    NM_022615                   137 bp             −3.33         0.997              2.00
  GCTTTGGGACTCAGCTTCAT                                                                                                                                      
  UCP1                     CAGGCTTCCAGTACTATTAGG                                   NM_012682                   181 bp             −3.40         0.983              1.97
  CTCTCCCTGAAGAGAAGTACT                                                                                                                                     
  UCP2                     CAAGGAGAGAGTCAAGGGCTA                                   NM_019354                   209 bp             −3.08         0.998              2.11
  GACTCTGAGCCCTTGGTGTAG                                                                                                                                     
  UCP3                     CTCGGTACCATCCTGACTAT                                    NM_013167                   149 bp             −3.47         0.982              1.94
  GTTCCTTTGGGGGTGTAGAA                                                                                                                                      
  VEGFA                    GTTCATGGACGTCTACCAGC                                    NM_031836                   253 bp             −3.62         0.973              1.89
  GCTATGCTGCAGGAAGCTCA                                                                                                                                      
  VEGFB                    GTGTCCCAGTTTGATGGCC                                     NM_053549                   187 bp             −3.45         1.000              1.95
  CGTCAGGACAGCAGCCAC                                                                                                                                        
  YWHAZ                    GACGGAAGGTGCTGAGAAA                                     NM_013011                   198 bp             −3.13         0.986              2.09
  GCAGCAACCTCAGCCAAGT                                                                                                                                       

^\#^Coefficient of determination of the standard curve.

\*The efficiency is determined by \[10^(−1/-slope^\].

###### 

Average expression stability ranking of six candidate reference genes

  **Ranking**     **Gene**   **M value**
  -------------- ---------- -------------
  Most stable      YWHAZ        0.056
                    TOP1        0.060
                    CANX        0.060
                    MDH1        0.062
                   ATP5B        0.073
  Least stable     RPL13        0.074

Ranking of the candidate reference genes according to their stability score M as calculated by the Microsoft Excel-based application GeNorm.

Western blotting
----------------

Homogenates were prepared and protein concentration was determined as described recently \[[@B11]\]. After protein separation by 12.5% SDS-PAGE the proteins were transferred to a nitrocellulose membrane and incubated with primary antibodies against PGC-1α (polyclonal anti-PGC-1α antibody; Millipore, Temecula, CA) and novel organic cation transporter 2 (OCTN2) (polyclonal anti-OCTN2 antibody; Lifespan Bioscience, Inc., Seattle, US) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (monoclonal anti-GAPDH antibody, Abcam, Cambridge, UK) as a reference protein. The membranes were washed, and then incubated with a horseradish peroxidase conjugated secondary monoclonal anti-mouse-IgG antibody (Sigma-Aldrich, Steinheim, Germany) for GAPDH and polyclonal anti-rabbit-IgG antibody (DakoCytomation, Glostrup, Denmark) for PGC-1α and OCTN2 at room temperature. Afterwards blots were developed by ECL Select (GE Healthcare, Munich, Germany) and the intensities of the specific bands were detected with a Bio-Imaging system (Syngene, Cambridge, UK) and quantified by Syngene Gene Tools software (nonlinear dynamics).

Statistics
----------

Statistical analysis of all data was done by one-way ANOVA using the Minitab Statistical Software (Rel. 13.0, State College, PA, USA). Means of the three groups were compared by Fisher's multiple range tests. Means were considered significantly different for *P* \< 0.05. Data presented are shown as means ± SEM.

Results
=======

Feed intake and body weight development
---------------------------------------

Initial and final body weights as well as daily body weight gain were greater in the obese control group and the obese carnitine group than in the lean control group (*P* \< 0.05; Table [3](#T3){ref-type="table"}). Similarly, feed intake was greater in the obese control group and the obese carnitine group than in the lean control group (*P* \< 0.05; Table [3](#T3){ref-type="table"}). The feed conversion ratio which describes gram feed per gram body weight gain was increased significantly in the lean control group (*P* \< 0.05; Table [3](#T3){ref-type="table"}). These parameters did not differ between the two obese groups.

###### 

**Feed intake and body weight gains of lean rats (lean control), obese Zucker rats fed a control diet (obese control) or obese Zucker rats fed a diet supplemented with 3 g/kg diet carnitine (obese carnitine) for 4 wk**^**1**^

                                                     **Lean**        **Obese**        **Obese**
  ---------------------------------------------- ---------------- ---------------- ----------------
  Feed intake (g/d)                               19.7 ± 0.2^c^    25.2 ± 0.5^b^    26.4 ± 0.4^a^
  Initial body weight (g)                           271 ± 3^b^       357 ± 6^a^       358 ± 7^a^
  Final body weight (g)                             367 ± 4^b^       501 ± 7^a^       496 ± 9^a^
  Daily body weight gain (g)                      3.35 ± 0.08^b^   5.03 ± 0.13^a^   4.85 ± 0.14^a^
  Feed conversion ratio (g feed/g body weight)    5.90 ± 0.11^a^   5.02 ± 0.09^b^   5.18 ± 0.18^b^

^1^Data are expressed as means ± SEM, n = 12 rats/group. Means in a row without a common letter differ (*P* \< 0.05).

Concentration of carnitine in plasma and M. rectus femoris
----------------------------------------------------------

In line with recent observations, the obese control group had lower concentrations of free carnitine, acetyl-carnitine and total carnitine (= sum of free carnitine and acetyl-carnitine) in plasma and rectus femoris muscle than the lean control group (*P* \< 0.05; Table [4](#T4){ref-type="table"}**)**. Due to carnitine supplementation concentrations of free carnitine, acetyl-carnitine and total carnitine in plasma and rectus femoris muscle were greater in the obese carnitine group than in the lean control group (*P \<* 0.05; Table [4](#T4){ref-type="table"}).

###### 

**Plasma and muscle (*M. rectus femoris*) concentrations of carnitine, plasma concentrations of TG and NEFA and liver concentration of TG in lean rats (lean control), obese Zucker rats fed a control diet (obese control) or obese Zucker rats fed a diet supplemented with 3 g/kg diet carnitine (obese carnitine) for 4 wk**^**1**^

                                     **Lean**        **Obese**        **Obese**
  ------------------------------ ---------------- ---------------- ----------------
  *Plasma (μmol/l)*                                                
   Total carnitine                62.3 ± 1.9^b^    40.0 ± 1.1^c^    90.5 ± 2.9^a^
   Free carnitine                 50.8 ± 1.6^b^    33.7 ± 1.2^c^    73.2 ± 2.5^a^
   Acetyl-carnitine               11.5 ± 0.9^b^     6.3 ± 0.3^c^    17.3 ± 0.8^a^
  *M. rectus femoris (nmol/g)*                                     
   Total carnitine                 919 ± 13^b^      752 ± 13^c^      1165 ± 19^a^
   Free carnitine                  742 ± 12^b^       590 ± 9^c^      937 ± 21^a^
   Acetyl-carnitine                 176 ± 4^b^       161 ± 4^b^       228 ± 6^a^
  *Plasma (mmol/l)*                                                
   TG                             1.42 ± 0.06^c^   6.35 ± 0.18^a^   4.42 ± 0.26^b^
   NEFA                           0.73 ± 0.06^c^   3.53 ± 0.16^a^   2.41 ± 0.18^b^
  *Liver (μmol/g)*                                                 
   TG                             10.2 ± 0.9^b^    87.7 ± 13.7^a^   65.6 ± 8.1^a^

^1^Data are expressed as means ± SEM, n = 12 rats/group. Means in a row without a common letter differ (*P* \< 0.05).

Lipid concentrations in plasma and liver
----------------------------------------

As expected, rats of the obese groups had greater levels of TG and NEFA in plasma and TG in the liver than those of the lean group (*P* \< 0.05; Table [4](#T4){ref-type="table"}). Due to carnitine supplementation, however, concentrations of TG and NEFA in plasma and TG in the liver were approximately 25--30% lower in the obese carnitine group than in the obese control group (*P* \< 0.05; Table [4](#T4){ref-type="table"}).

Fiber type composition and expression of myosin heavy chain isoforms in M. rectus femoris
-----------------------------------------------------------------------------------------

Muscle fiber typing revealed an approximately 18% lower percentage of type I muscle fibers in rectus femoris muscle in the obese control group than in the lean control group. Interestingly, the type I muscle fiber percentage in rectus femoris muscle did not differ between the obese carnitine group and the lean control group indicating that carnitine supplementation prevented obesity-induced type I to type II fiber transition (*P* \< 0.05; Figure [1](#F1){ref-type="fig"}A, B). In contrast, the type II fiber percentage in rectus femoris muscle was greater in the obese control group than in the other two groups (*P* \< 0.05; Figure [1](#F1){ref-type="fig"}A, B), but it did not differ between the obese control group and the lean control group. The composition of muscle fiber types in rectus femoris muscle did not differ between the lean control and the obese carnitine group. Relative mRNA levels of genes encoding the different myosin heavy-chain II isoforms (MHCIIa encoded by MYH2, MHCIIb encoded by MYH4, MHCIIx encoded by MYH1) did not differ between the groups (Figure [1](#F1){ref-type="fig"}C). However, the relative mRNA level of MHCIb (encoded by MYH7), which encodes the type I fiber specific myosin heavy chain isoform; in rectus femoris muscle was greater in the lean control and the obese carnitine group than the obese control group (*P* \< 0.05; Figure [1](#F1){ref-type="fig"}B).

![**Fiber distribution of*M. rectus femoris*of lean rats (lean control), Zucker rats fed a control diet (obese control) or Zucker rats fed a diet supplemented with 3 g/kg diet carnitine (obese carnitine) for 4 wk. (A)** muscle fiber type composition, **(B)** fiber type-specific cross-sectional area, **(C)** relative mRNA expression of myosine heavy chain isoforms. Bars represent means ± SEM, n = 12 rats/group. Means without a common letter differ (*P* \< 0.05).](1743-7075-10-48-1){#F1}

Expression of genes involved in muscle fiber transformation in M. rectus femoris
--------------------------------------------------------------------------------

The mRNA levels of the main regulators of muscle fiber transformation PPARδ (encoded by PPARD), PGC-1α (encoded by PPARGC1A) and PGC-1β (encoded by PPARGC1B) in rectus femoris muscle were greater in the obese carnitine than in obese control group (*P* \< 0.05; Table [5](#T5){ref-type="table"}). The lean control and the obese control group did not differ with regard to these genes.

###### 

**Relative mRNA levels of genes involved in carnitine uptake, fatty acid transport, fatty acid utilization, and glucose uptake and glycolysis in*M. rectus femoris*of lean rats (lean control), obese Zucker rats fed a control diet (obese control) or obese Zucker rats fed a diet supplemented with 3 g/kg diet carnitine (obese carnitine) for 4 wk**^**1**^

                                             **Lean**            **Obese**        **Obese**
  ----------------------------------- ----------------------- ---------------- ----------------
                                       Fold of obese control                   
  *Muscle fiber transformation*                                                
   PPARD                                  1.11 ± 0.19^b^       1.00 ± 0.12^b^   4.18 ± 0.58^a^
   PPARGC1A                               1.21 ± 0.17^b^       1.00 ± 0.16^b^   2.14 ± 0.42^a^
   PPARGC1B                               0.78 ± 0.06^b^       1.00 ± 0.24^b^   2.02 ± 0.24^a^
  *Carnitine uptake*                                                           
   SLC22A5                                0.92 ± 0.12^b^       1.00 ± 0.08^b^   1.90 ± 0.25^a^
  *Fatty acid transport and uptake*                                            
   FABP3                                  1.05 ± 0.28^b^       1.00 ± 0.34^b^   2.18 ± 0.46^a^
   SLC27A1                                  1.19 ± 0.34         1.00 ± 0.23      1.46 ± 0.30
   CD36                                   0.71 ± 0.14^b^       1.00 ± 0.11^b^   1.52 ± 0.20^a^
   LPL                                    1.14 ± 0.22^b^       1.00 ± 0.28^b^   2.22 ± 0.35^a^
  *β-oxidation*                                                                
   ACADM                                  1.79 ± 0.44^b^       1.00 ± 0.20^b^   3.39 ± 0.86^a^
   ACADL                                  1.11 ± 0.23^b^       1.00 ± 0.24^b^   2.25 ± 0.61^a^
  *Carnitine shuttle*                                                          
   CPT1B                                    1.25 ± 0.31         1.00 ± 0.35      1.49 ± 0.27
   SLC25A20                               1.46 ± 0.14^a^       1.00 ± 0.07^b^   1.39 ± 0.13^a^
  *Glucose uptake and glycolysis*                                              
   SLC2A4                                   1.41 ± 0.34         1.00 ± 0.32      1.52 ± 0.18
   HK2                                    1.32 ± 0.37^b^       1.00 ± 0.51^b^   3.11 ± 0.18^a^
   PKM                                      1.87 ± 0.94         1.00 ± 0.33      2.36 ± 0.46
   PFKM                                     1.20 ± 0.51         1.00 ± 0.32      1.23 ± 0.25

^1^Data are expressed as means ± SEM, n = 12 rats/group. Means and SEM of the other groups were presented as fold of the obese control group, which mean was set to 1. Means in a row without a common letter differ (*P* \< 0.05).

The relative protein level of PGC-1α in rectus femoris muscle was also greater in the obese carnitine group than in the obese control and the lean control group (*P* \< 0.05; Figure [2](#F2){ref-type="fig"}). The relative protein level of PPARδ in rectus femoris muscle was 33% higher in the obese carnitine group than in the obese control group but this effect was not significant (Figure [2](#F2){ref-type="fig"}).

![**Relative protein level of PGC-1α (A) and PPARδ (B) in*M. rectus femoris*of lean rats (lean control), Zucker rats fed a control diet (obese control) or Zucker rats fed a diet supplemented with 3 g/kg diet carnitine (obese carnitine) for 4 wk.** Bars represent means ± SEM, n = 6/group. Means without a common letter differ (*P* \< 0.05). **(C)** Representative immunoblots specific to PGC-1α, PPARδ and GAPDH as internal control are shown for one animal per group; immunoblots for the other animals revealed similar results.](1743-7075-10-48-2){#F2}

Expression of genes involved in carnitine uptake, fatty acid transport, fatty acid utilization, and glycolysis in M. rectus femoris
-----------------------------------------------------------------------------------------------------------------------------------

The mRNA levels of genes involved in carnitine uptake \[SLC22A5 encoding organic cation/carnitine transporter (OCTN2)\], fatty acid transport and uptake (FABP3 encoding fatty acid binding protein 3, CD36 encoding fatty acid translocase/CD36, LPL encoding lipoprotein lipase), β-oxidation (ACADL, ACADM encoding long chain acyl-CoA dehydrogenase and medium chain acyl-CoA dehydrogenase, respectively), carnitine shuttle (SLC25A20 encoding carnitine/acylcarnitine translocase), and glycolysis (HK2 encoding hexokinase 2) in rectus femoris muscle were greater in the obese carnitine group than in the obese control group (*P* \< 0.05; Table [5](#T5){ref-type="table"}). The mRNA levels of SLC27A1 encoding fatty acid transport protein, CPT1B (encoding carnitine-palmitoyl transferase 1b), SLC2A4 encoding glucose transporter-4, PKM (pyruvate kinase, muscle), and PFKM (encoding phosphofructokinase, muscle) in rectus femoris muscle were numerically greater in the obese carnitine group than in the obese control group, but the differences were not significant (Table [5](#T5){ref-type="table"}).

The relative protein level of OCTN2 in rectus femoris muscle was also greater in the obese carnitine group than in the other groups (*P* \< 0.05; Figure [3](#F3){ref-type="fig"}).

![**Relative protein level of OCTN2 in*M. rectus femoris*of lean rats (lean control), Zucker rats fed a control diet (obese control) or Zucker rats fed a diet supplemented with 3 g/kg diet carnitine (obese carnitine) for 4 wk. (A)** Bars represent means ± SEM, n = 6/group. Means without a common letter differ (*P* \< 0.05). **(B)** Representative immunoblots specific to OCTN2 and GAPDH as internal control are shown for one animal per group; immunoblots for the other animals revealed similar results.](1743-7075-10-48-3){#F3}

Expression of genes involved in angiogenesis, tricarboxylic acid cycle and mitochondrial respiratory chain and thermo genesis in M. rectus femoris
--------------------------------------------------------------------------------------------------------------------------------------------------

Relative mRNA levels of genes encoding vascular endothelial growth factor b (VEGFB), succinate dehydrogenase subunit A (SDHA) and uncoupling proteins (UCP1 and UCP2) in rectus femoris muscle were greater in the obese carnitine group than in the obese control and the lean control group (*P* \< 0.05; Table [6](#T6){ref-type="table"}). The mRNA level of UCP3 in rectus femoris muscle was numerically greater in the obese carnitine group than in the obese control and lean control group, but this effect was not significant (Table [6](#T6){ref-type="table"}).

###### 

**Relative mRNA levels of genes involved in angiogenesis, mitochondrial respiratory chain and uncoupling proteins in*M. rectus femoris*of lean rats (lean control), obese Zucker rats fed a control diet (obese control) or obese Zucker rats fed a diet supplemented with 3 g/kg diet carnitine (obese carnitine) for 4 wk**^**1**^

                                             **Lean**            **Obese**        **Obese**
  ----------------------------------- ----------------------- ---------------- ----------------
                                       Fold of obese control                   
  *Angiogenesis*                                                               
  VEGFA                                     0.81 ± 0.18         1.00 ± 0.30      1.30 ± 0.37
  VEGFB                                   1.62 ± 0.35^ab^      1.00 ± 0.19^b^   2.21 ± 0.28^a^
  *TCA cycle and respiratory chain*                                            
  SDHA                                    1.26 ± 0,25^ab^      1.00 ± 0.24^b^   2.18 ± 0.40^a^
  *Thermogenesis*                                                              
  UCP1                                    1.67 ± 0.35^b^       1.00 ± 0.12^b^   7.06 ± 1.27^a^
  UCP2                                    1.07 ± 0.23^b^       1.00 ± 0.24^b^   3.39 ± 0.34^a^
  UCP3                                      0.97 ± 0.20         1.00 ± 0.25      1.92 ± 0.70

^1^Data are expressed as means ± SEM, n = 12 rats/group. Means and SEM of the other groups were presented as fold of the obese control group, which mean was set to 1. Means in a row without a common letter differ (*P* \< 0.05).

Discussion
==========

In the present study we tested the hypothesis that carnitine supplementation to obese Zucker rats counteracts the obesity-induced muscle fiber transition from type I to type II and, thereby, improves fatty acid utilization in skeletal muscle. The dietary carnitine dosage (3 g/kg diet) fed to the rats related to 156 to 216 mg/kg body weight based on an average daily feed consumption of 26 g and a body weight of 360 (initial) to 500 (final) g. This carnitine dosage is slightly higher when compared to that used in clinical studies with human subjects with different metabolic disorders in which carnitine dosages of up to 4 g/d corresponding to 60 mg/kg body weight for an individual weighing 70 kg were found to be effective \[[@B28]\]. A key finding of the present study is that carnitine supplementation to obese rats resulted in an increased number of type I fibers and a decreased number of type II fibers in rectus femoris muscle when compared to non-supplemented obese rats. This indicates that carnitine induces type II to type I fiber transition in femoris muscle of obese rats which was also confirmed by the finding that the type I fiber specific MYH7 mRNA level in rectus femoris muscle was markedly elevated in the obese carnitine group. Interestingly, the fiber type distribution of rectus femoris muscle was similar between the obese carnitine and the lean control group, whereas rectus femoris muscle of the obese control group had a lower number of type I fibers and a greater number of type II fibers compared to that of the lean control group. A reduction of type I fibers and a lower oxidative enzyme activity in muscle of obese and diabetic rodent models compared to lean models has been well documented \[[@B6],[@B7]\]. In addition, several studies reported that obese subjects have a decreased proportion of type I muscle fibers and an overall decrease in mitochondrial enzymes indicating that muscle oxidative capacity is impaired in obese subjects \[[@B29]-[@B32]\], which likely contributes to the impaired whole body fatty acid utilization and the elevated blood lipid levels in these subjects. Moreover, it was shown that insulin sensitivity correlates positively with the proportion of type I muscle fibers and negatively with the proportion of type II muscle fibers \[[@B29]-[@B31]\]. There is a large body of evidence that carnitine supplementation improves glucose tolerance in insulin resistant and/or diabetic humans (reviewed by \[[@B28]\]). The observed up-regulation of genes in involved in glycolysis (HK2) by carnitine in muscle of the obese rats is also supportive of a beneficial effect of carnitine on glucose homeostasis. Insulin resistant and/or diabetic subjects are likely particularly sensitive to carnitine supplementation because diabetic subjects were reported to have diminished plasma free carnitine concentrations, even though the levels were still within or only slightly below the physiological range (25--50 μmol/l) reported for healthy subjects \[[@B33]-[@B35]\]. Given the observed increase in type I muscle fiber proportion in obese rats and the relationship between type I muscle fiber proportion and insulin sensitivity it is not unlikely that the improvement of glucose tolerance and insulin sensitivity by carnitine supplementation in obese and diabetic subjects is due to the effect of carnitine on muscle fiber distribution. Even though a very recent study reported that carnitine supplementation at a non-physiologically high dosage promoted intestinal formation of the proatherogenic trimethylamine-N-oxide and accelerated atherosclerosis development in mice \[[@B36]\], the fact that none of the carnitine supplementation studies in humans reported any adverse effects even at very high dosages (e.g., 4 g oral carnitine) indicates that safety concerns with carnitine supplementation are unfounded. Collectively, the present findings corroborate our hypothesis that carnitine supplementation to obese rats counteracts the obesity-induced muscle fiber transition from type I to type II and is able to restore the muscle fiber distribution and the oxidative metabolic phenotype observed in lean animals.

This study showed that carnitine supplementation in obese rodents resulted in a higher type I muscle fiber content compared to obese rats without carnitine supplementation. The observed decrease of carnitine levels in plasma and muscle in the obese control group is consistent with observations from recent studies showing that whole body carnitine status is strongly compromised in rodent models of genetic and diet-induced obesity and diabetes \[[@B10]\]. As the main reason for this phenomenon an impaired hepatic carnitine biosynthesis has been identified \[[@B10],[@B11]\]. In contrast, carnitine supplementation to obese and/or diabetic rodent models is able to restore the carnitine status to normal \[[@B10]\] or even supraphysiological levels as shown herein. Although our observations do not proof a causal link between carnitine status and muscle fiber distribution, our results suggest that the carnitine-induced change in muscle fiber distribution is due to an improvement of carnitine status.

In addition, the present study shows that the carnitine-induced change in the contractile phenotype of skeletal muscle of obese rats is also accompanied by a change in the metabolic phenotype. In agreement with the high content of mitochondria and the preferential use of fatty acids for energy production of type I fibers, genes involved in fatty acid transport and uptake (FABP3, CD36, LPL), β-oxidation (ACADL, ACADM), carnitine shuttle (SLC25A20), carnitine uptake (SLC22A5) and TCA cycle and respiratory chain (SDHA) in femoris muscle were strongly up-regulated in the obese carnitine compared to the obese control group. In line with our findings in skeletal muscle, carnitine supplementation was also shown to stimulate TCA activity, mitochondrial respiration and ATP production in the diabetic rat heart \[[@B37],[@B38]\]. Thus, these carnitine-induced effects on gene expression of rectus femoris muscle are indicative of an improved capacity of the muscle for oxidative utilization of fatty acids. Since skeletal muscle significantly contributes to whole-body fatty acid utilization, the improved oxidative metabolic phenotype of skeletal muscle at least partially explains the pronounced NEFA- and TG-lowering effects of carnitine supplementation observed in the present rat model of obesity and insulin resistance but also in other studies \[[@B39]\].

To gain insight into the mechanisms underlying muscle fiber transition we determined the mRNA and/or protein levels of the main regulators of fiber composition. The two main regulators of type II to type I fiber transition, mitochondrial biogenesis, and oxidative enzyme expression, PPARδ and PGC-1α, but also PGC-1β, which induces similar effects as PGC-1α on the contractile and metabolic phenotype of skeletal muscle \[[@B40],[@B41]\], were clearly stronger expressed in rectus femoris muscle of the obese carnitine group than in the obese control group. Regarding that PGC-1α and PGC-1β also regulate angiogenesis through inducing the expression of angiogenic factors like VEGFs, we also determined transcript levels of VEGFA (encoding VEGFa) and VEGFB (encoding VEGFb). VEGFb particularly favors the utilization of fatty acids not only by increasing capillary density and thereby blood perfusion but also by inducing the expression of fatty acid transport proteins (FATPs, CD36) \[[@B42]\]. Correspondingly, VEGFb is mainly expressed in tissues with high mitochondria content and with preferential use of fatty acids as energy source like oxidative skeletal muscle, heart, and brown adipose tissue \[[@B43]\]. The observation that the relative mRNA level of VEGFB was markedly elevated in the obese carnitine group is therefore in line with the induction of PGC-1α and PGC-1β and provides a further indication for the improved oxidative phenotype of rectus femoris muscle in rats of the obese carnitine group. Collectively, our findings strongly suggest that the up-regulation of genes encoding PGC-1α, PGC-1β, and PPARδ in rectus femoris muscle by L-carnitine supplementation is responsible for the observed type II to type I fiber transition and the oxidative metabolic phenotype of skeletal muscle of obese Zucker rats.

In conclusion, the results of this study demonstrate that carnitine supplementation to obese Zucker rats significantly improves carnitine status, counteracts the obesity-induced muscle fiber transition from type I to type II and favors an oxidative metabolic phenotype of skeletal muscle which preferentially uses fatty acids as energy source. The enhanced capacity of skeletal muscle to utilize fatty acids was demonstrated by the carnitine-induced up-regulation of genes involved in fatty acid uptake and transport, carnitine uptake, fatty acid β-oxidation, mitochondrial fatty acid uptake (carnitine shuttle system) and tricarboxylic acid cycle. These metabolic changes in skeletal muscle are likely to contribute to the pronounced NEFA- and TG-lowering effects of carnitine supplementation in obese Zucker rats. Therefore, carnitine supplementation is supposed to be beneficial for the treatment of elevated levels of metabolic fuels (e.g., fatty acids) which are frequently found in subjects with obesity, insulin resistance, diabetes or metabolic syndrome.
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